A NEW SUBSIDIARY OF SCINTOMICS: APPLIED THERANOSTIC TECHNOLOGIES >ATT<
ATT is a recently founded subsidiary of Scintomics and continues and expands Scintomics´ radiopharmaceutical business segment in an independent manner with a particular strategic emphasis on providing unrestricted supply and support of Scintomics´ proprietary and innovative tracer technology and non-IP protected precursors. Read more
"We want to establish F-18-PSMA and its 800-seconds-production in our hospital? Who should I contact?"
If you like to exploit the outstanding features of the F-18 Radiohybrid PSMA in your hospital please visit SCINTOMICS MOLECULAR - APPLIED THERANOSTICS TECHNOLOGIES or send an email to info(at)appliedtheranostics.com. Read more
AVAILABLE: PSMA I&T GMP Grade
Precursor for Lu-177 or Ac-225 PSMA I&T in GMP Quality at ATT (Applied Theranostics Technologies)
Radiohybrid PSMA-targeted Agents for Prostate Cancer licensed to Blue Earth Diagnostics
MUNICH, May 2018 – SCINTOMICS has signed an exclusive, worldwide agreement with Blue Earth Diagnostics, a leading molecular imaging diagnostics company. Under the terms of the agreement, Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.